GSK plc (GSK) Balance Sheet

The swings appear driven more by fluctuations in equity, which ranged from $13.7B to $23.5B, than by a steady build in total debt, which stayed between $16.1B and $25.1B. This pattern may indicate that retained earnings volatility, rather than deliberate deleveraging, is the main driver of the balance sheet trajectory. Investors should monitor whether the 2026Q3 rise in debt toward $23.9B reflects strategic funding or a reversal of the recent improvement.

The gap between gross debt and cash suggests reliance on capital markets access to support operations and shareholder distributions. The current ratio falling to 0.86 in 2026Q3 implies thinner short-term liquidity coverage relative to the 0.78 to 0.87 range seen across the period. This may indicate that refinancing timing and the size of near-term maturities deserve closer scrutiny than the headline debt-to-equity figure alone conveys.

Goodwill growth alongside a PP&E base that has stayed roughly between $9.7B and $13.6B may reflect bolt-on acquisition activity consistent with management's stated pipeline strategy. The rising share of non-tangible assets suggests impairment exposure could become material if specialty pipeline outcomes disappoint. Investors should treat the asset quality as dependent on the continued commercial success of acquired franchises.

The volatility in retained earnings points to sensitivity of reported equity to non-recurring charges and legal provisions rather than a steady accumulation of profits. Equity of $18.9B against total assets of $72.2B yields a relatively modest equity cushion, which may leave less room to absorb large litigation outcomes. This warrants further investigation into how adjusted and statutory earnings are being reconciled within equity.

The steady erosion of cash from 2025 levels, combined with a current ratio below 1.0, may indicate limited capacity to absorb an unexpected legal settlement or a sudden shift in vaccine procurement timing without drawing on debt markets. The company's reliance on operating cash generation to fund both R&D and distributions appears to make this buffer a key monitoring point. Investors should weigh this against the company's historically stable access to credit.